Myelodysplastic Syndromes Clinical Trials

Not all trials are listed on www.ClinicalTrials.gov. The investigators may have chosen not to register the trial, or the study may not be eligible to be listed on ClinicalTrials.gov. If the study has not, for example, been approved by a human subject review board, it cannot be posted. Some trials are not listed because the investigators are not planning to publish the research findings, so you can ask the study coordinator why the study has not been included on ClinicalTrials.gov before you give your consent to participate.

The information on the studies linked below is provided strictly as a resource, not as an endorsement of any given treatment, doctor, or medical center.

Remember, before you sign a consent form, Clinical Trials Explained can help you understand the potential risks and benefits of a clinical trial. You can also contact the AA&MDSIF staff to discuss any questions you have at clinicaltrials@aamds.org or by calling the office at 301.279.7202 or 800.747.2820.

^{Last Modified: February 2009}

Fox Chase � Temple University, BMT Program

Fludarabine and Melphalan Followed by Healthy Donor Stem Cell Transplantation for Hematologic Malignancies

Protocol 121 | Philadelphia, Pennsylvania

This is a phase II trial using fludarabine-based regimen to evaluate the efficacy of mini-allogeneic blood stem cell transplantation to treat myelodysplastic syndromes. Eligible patients must have HLA identical donor available, be under age 70 and platelet or red cell transfusion dependent. Patients with matched related donors will be considered up to age 70 with Karnofsky Performance Scale > 80%. Patients with matched unrelated donor (MUD) will be considered to age 65 only. Contact 215.214.4191 for referral info. Kenneth F. Mangan, MD, is the Principal Investigator for this protocol.

For patients with: MDS

Updated: December 13, 2007

<< Return to List